Cargando…

Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective

Life-prolonging central nervous system active systemic therapies for metastatic NSCLC have increased the complexity of managing brain metastases (BMs). Australian medical oncologists, radiation oncologists, and neurosurgeons discussed the evidence guiding the diverse clinical approaches to the manag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chee Khoon, Soon, Yu Yang, Jeffree, Rosalind L., Joshi, Rohit, Koh, Eng-Siew, Lam, Wei-Sen, Le, Hien, Lwin, Zarnie, Pinkham, Mark B., Siva, Shankar, Ng, Evan, John, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472312/ https://www.ncbi.nlm.nih.gov/pubmed/37663675 http://dx.doi.org/10.1016/j.jtocrr.2023.100553

Ejemplares similares

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma
por: Kong, Benjamin Y, et al.
Publicado: (2022)

A qualitative study of cancer care professionals’ experiences of working with migrant patients from diverse cultural backgrounds
por: Broom, Alex, et al.
Publicado: (2019)

Scoping the psychological support practices of Australian health professionals working with people with primary brain tumor and their families
por: Ownsworth, Tamara, et al.
Publicado: (2022)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
por: Florez (DUMA), Narjust, et al.
Publicado: (2023)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
por: Persinger, Rasheda
Publicado: (2021)

Cutaneous metastases as a presenting sign of metastatic NSCLC
por: McSweeney, William T, et al.
Publicado: (2019)

The road of NSCLC stem cells toward bone metastases
por: Bertolini, Giulia, et al.
Publicado: (2022)

Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States Are Maintained in 3D Culture
por: D’Souza, Rochelle C. J., et al.
Publicado: (2020)

LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study
por: Kong, Benjamin Y, et al.
Publicado: (2021)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Barriers and potential solutions to international collaboration in neuro‐oncology clinical trials: Challenges from the Australian perspective
por: Kong, Benjamin Y., et al.
Publicado: (2021)

Disseminated disease including intra-cardiac metastasis from intermediate trophoblastic tumor of unspecified subtype, presenting in pregnancy
por: Xu, Wen, et al.
Publicado: (2016)

Traveling With Cancer: A Guide for Oncologists in the Modern World
por: Heng, Sharon, et al.
Publicado: (2019)

COVID-19 and the cancer care workforce: From doctors to ancillary staff
por: Gasper, Harry, et al.
Publicado: (2020)

Exploring the impact and experience of fractional work in medicine: a qualitative study of medical oncologists in Australia
por: Kirby, Emma, et al.
Publicado: (2019)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study
por: Shen, Fangfang, et al.
Publicado: (2022)

Factors that influence clinical trial participation by patients with cancer in Australia: a scoping review protocol
por: You, Kyung Ha, et al.
Publicado: (2022)

Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery
por: Gao, Hong Xiang, et al.
Publicado: (2018)

Predictive effect of DCE-MRI and DWI in brain metastases from NSCLC
por: Ye, Chengyu, et al.
Publicado: (2021)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
por: Nicoś, Marcin, et al.
Publicado: (2022)

An Injury Paradigm to Investigate Central Nervous System Repair in Drosophila
por: Kato, Kentaro, et al.
Publicado: (2013)

Artificial nervous systems—A new paradigm for artificial intelligence
por: Narcross, Fredric
Publicado: (2021)

Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases
por: Lim, Malcolm, et al.
Publicado: (2019)

Uterine leiomyosarcoma with central nervous system metastases
por: Abrahão, Carina Meira, et al.
Publicado: (2015)

Cytokine Landscape in Central Nervous System Metastases
por: Marin, Julie, et al.
Publicado: (2022)

“It doesn’t exist…”: negotiating palliative care from a culturally and linguistically diverse patient and caregiver perspective
por: Kirby, Emma, et al.
Publicado: (2018)

Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
por: Ikarashi, Daiki, et al.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_llj0br7i586qrc77k2t0coll7b